Salt: Lapatinib
Therapeutic Description: Cytostatics
Category: Protein kinase inhibitor.
Pregnancy: Contraindicated in pregnancy.
Lactation: Contraindicated or not recommended.
Contraindications: Ensure adequate contraception.
Precautions: Severe renal or hepatic impairment, monitor LFTs, caution in patients in conditions that impair left ventricular function; monitor for pulmonary toxicity. Risk factor for QT prolongation, monitor let ventricular ejection fraction (LVEF).
Advanced or metastatic breast-cancer in patients with tumours that over express human epidermal growth factor receptor-2 (HER2). In combination with capecitabine, for patients who have had previous treatment with an anthracycline, a taxane, and trastuzumab, or for post-menopausal women in com
CYP3A4 inhibitors (ritonavir, azole antifungals, nefazodone, telithromycin) or inducers (carbamazepine, rifampin, phenytoin), drugs that increase gastric pH, drugs that prolong QT interval, verapamil, cyclosporin, digoxin, erythromycin, irinotecan, rosuvastatin, paclitaxel.
Diarrhoea, decrease LVEF, rash, GI upsets, stomatitis, anorexia, fatigue, headache, dry skin, hyperbilirubinaemia, hepatotoxicity, back pain, insomnia, mucosal inflammation, cough, dyspnoea, alopecia, pruritus, arrhythmia.
Strength Pack Size PKR
250 mg70's94103.10

Your medicine formula resulted in the following types of medicine type. Please select to proceed.